Can a cancer drug help heart transplant patients get a match?
NCT ID NCT05300451
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether the drug daratumumab can lower high levels of immune system antibodies that make it hard for some people to find a matching heart donor. Ten adults waiting for a heart transplant will receive daratumumab injections to see if their antibody levels drop enough to allow a successful transplant. The goal is to reduce the risk of organ rejection and improve chances of receiving a donor heart.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- daratumumab and hyaluronidase-fihj (DARZALEX FASPRO)
- What this could lead to
- If successful, this could help people with high antibody levels become eligible for a heart transplant and reduce the risk of organ rejection.
- What could go wrong
- This is a very small early-phase trial with only 10 participants, so results may not apply to everyone. Daratumumab can cause infusion reactions and increase infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIAC TRANSPLANT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.